[go: up one dir, main page]

EA201791734A1 - Способ лечения воспалительных заболеваний - Google Patents

Способ лечения воспалительных заболеваний

Info

Publication number
EA201791734A1
EA201791734A1 EA201791734A EA201791734A EA201791734A1 EA 201791734 A1 EA201791734 A1 EA 201791734A1 EA 201791734 A EA201791734 A EA 201791734A EA 201791734 A EA201791734 A EA 201791734A EA 201791734 A1 EA201791734 A1 EA 201791734A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inflammatory diseases
treating inflammatory
spa
treating
spondylarthritis
Prior art date
Application number
EA201791734A
Other languages
English (en)
Inventor
Маттиас Арндт
Стелла Асланян
Мэри Рут Флэк
Аннетте Беттина Галлер
Боян Лаловиц
Стивен Джон Падула
Пол Рассел Шолль
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201791734A1 publication Critical patent/EA201791734A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение в целом относится к способам лечения связанных с IL-23 заболеваний, в особенности, воспалительных заболеваний, таких как псориаз, псориатический артрит или аксиальный (спинальный) спондилоартрит (ax-SpA), включая анкилозирующий спондилит и нерадиографический ax-SpA, используя анти-IL-23А антитела.
EA201791734A 2015-02-04 2016-02-02 Способ лечения воспалительных заболеваний EA201791734A1 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562111731P 2015-02-04 2015-02-04
US201562130876P 2015-03-10 2015-03-10
US201562135335P 2015-03-19 2015-03-19
US201562145764P 2015-04-10 2015-04-10
US201562204520P 2015-08-13 2015-08-13
US201562235631P 2015-10-01 2015-10-01
PCT/US2016/016061 WO2016126638A1 (en) 2015-02-04 2016-02-02 Methods of treating inflammatory diseases

Publications (1)

Publication Number Publication Date
EA201791734A1 true EA201791734A1 (ru) 2018-01-31

Family

ID=55453266

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791734A EA201791734A1 (ru) 2015-02-04 2016-02-02 Способ лечения воспалительных заболеваний

Country Status (15)

Country Link
US (1) US20160222102A1 (ru)
EP (1) EP3253794A1 (ru)
JP (7) JP6758304B2 (ru)
KR (2) KR20240158362A (ru)
CN (2) CN107206081A (ru)
AU (3) AU2016215535B2 (ru)
BR (1) BR112017014684A2 (ru)
CA (1) CA2972995A1 (ru)
CL (1) CL2017001960A1 (ru)
EA (1) EA201791734A1 (ru)
IL (2) IL307578A (ru)
MX (3) MX392789B (ru)
PH (1) PH12017501378A1 (ru)
SG (2) SG10202103879YA (ru)
WO (1) WO2016126638A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2816950C (en) 2010-11-04 2018-11-27 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
MX368653B (es) 2012-05-03 2019-10-10 Boehringer Ingelheim Int Anticuerpos anti-il-23p19.
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
MX388301B (es) 2014-09-03 2025-03-19 Boehringer Ingelheim Int Il-23a y tnf-alfa orientados y compuesto y sus usos.
MX392789B (es) * 2015-02-04 2025-03-21 Boehringer Ingelheim Int Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias
EP3744733A3 (en) * 2016-04-15 2021-02-24 Boehringer Ingelheim International GmbH Methods of treating inflammatory diseases
MX2019003703A (es) * 2016-09-30 2020-08-13 Janssen Biotech Inc Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
CN106778030B (zh) * 2017-01-10 2023-04-07 广州和康医疗技术有限公司 一种强直性脊柱炎病情监测管理系统及其监测管理方法
US11548941B2 (en) 2018-11-20 2023-01-10 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
CN111378045B (zh) * 2018-12-28 2022-08-02 长春金赛药业有限责任公司 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物
TW202123965A (zh) * 2019-09-09 2021-07-01 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
EP4469154A1 (en) * 2022-01-25 2024-12-04 Sun Pharmaceutical Industries Limited Methods for treatment of subjects with plaque psoriasis of the scalp
TW202511290A (zh) * 2023-09-07 2025-03-16 大陸商信達生物製藥（蘇州）有限公司 一種重組抗ＩＬ－２３ｐ１９抗體治療中重度銀屑病的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
ES2710289T3 (es) 2005-06-30 2019-04-24 Janssen Biotech Inc Anticuerpos anti-IL-23, composiciones, procedimientos y usos
MX2008002179A (es) 2005-08-25 2008-04-22 Lilly Co Eli Anticuerpos anti-il-23.
CA2620802A1 (en) * 2005-08-31 2007-03-08 Schering Corporation Engineered anti-il-23 antibodies
RS60616B1 (sr) 2005-12-29 2020-09-30 Janssen Biotech Inc Humana anti-il-23 antitela, kompozicije, postupci i upotrebe
NZ579158A (en) 2007-02-23 2012-01-12 Schering Corp Engineered anti-il-23p19 antibodies
CA2816950C (en) * 2010-11-04 2018-11-27 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
MX368653B (es) * 2012-05-03 2019-10-10 Boehringer Ingelheim Int Anticuerpos anti-il-23p19.
US9803010B2 (en) * 2012-06-27 2017-10-31 Merck Sharp & Dohme Corp. Crystalline anti-human IL-23p19 antibodies
SG10201804954UA (en) * 2013-03-15 2018-07-30 Amgen Inc Methods for treating psoriasis using an anti-il-23 antibody
MX392789B (es) 2015-02-04 2025-03-21 Boehringer Ingelheim Int Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias
JP7090014B2 (ja) * 2018-11-07 2022-06-23 株式会社ミツバ ロータ、モータ、ブラシレスワイパーモータ及びロータの製造方法

Also Published As

Publication number Publication date
MX2022006573A (es) 2022-07-11
JP2025060798A (ja) 2025-04-10
JP7042297B2 (ja) 2022-03-25
AU2016215535B2 (en) 2021-09-16
JP2020125338A (ja) 2020-08-20
AU2016215535A1 (en) 2017-07-13
SG11201705728RA (en) 2017-08-30
JP6758304B2 (ja) 2020-09-23
AU2021286378B2 (en) 2025-03-13
AU2021286378A1 (en) 2022-01-20
EP3253794A1 (en) 2017-12-13
IL253118A0 (en) 2017-08-31
JP7044824B2 (ja) 2022-03-30
CN113559258A (zh) 2021-10-29
MX2022006575A (es) 2022-07-11
JP2022081644A (ja) 2022-05-31
PH12017501378A1 (en) 2018-01-08
JP2020125339A (ja) 2020-08-20
KR20170120616A (ko) 2017-10-31
MX392789B (es) 2025-03-21
WO2016126638A1 (en) 2016-08-11
JP2025060797A (ja) 2025-04-10
JP2020125340A (ja) 2020-08-20
AU2025204286A1 (en) 2025-07-03
CA2972995A1 (en) 2016-08-11
NZ733136A (en) 2024-04-26
JP2018505882A (ja) 2018-03-01
SG10202103879YA (en) 2021-05-28
IL307578A (en) 2023-12-01
MX2017010037A (es) 2018-05-15
JP7042298B2 (ja) 2022-03-25
US20160222102A1 (en) 2016-08-04
CL2017001960A1 (es) 2018-04-20
BR112017014684A2 (pt) 2018-01-09
CN107206081A (zh) 2017-09-26
KR20240158362A (ko) 2024-11-04

Similar Documents

Publication Publication Date Title
EA201791734A1 (ru) Способ лечения воспалительных заболеваний
EA201890630A1 (ru) Антитела против pd-1 и способы их применения
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
MX2019009812A (es) Proteinas quimericas basadas en tigit y light.
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891532A1 (ru) Композиции и способы лечения гемоглобинопатий
MX391171B (es) Anticuerpos anti-cd19 humano con alta afinidad
EA201791422A1 (ru) Фармацевтические продукты и устойчивые жидкие композиции антител к il-17
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201791768A1 (ru) Иммуномодулирующие агенты
PH12018500578A1 (en) Methods of treating inflammatory diseases
HK1255331A1 (zh) 抗pcsk9抗體及其應用
EA202193002A2 (ru) Соединение, нацеленное на ил-23a и фно-альфа, и его применение
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201890572A1 (ru) Биофармацевтические композиции
EA201691541A1 (ru) Новые анти-baff антитела
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).